Genefluence deploys rapid PCR test for urinary tract infections at Royal Hospital Chelsea
Genefluence has launched its point-of-care PCR diagnostic tool for urinary tract infections at London's Royal Hospital Chelsea. The technology aims to provide rapid identification of bacterial resistance.
Genefluence has introduced a rapid PCR diagnostic platform designed to identify bacteria and antibiotic resistance genes associated with urinary tract infections (UTIs). The company confirmed the first clinical use of the system at the Royal Hospital Chelsea in London.
Unlike traditional diagnostics that require samples to be sent to external laboratories, this test is designed for point-of-care use. By enabling immediate results at the bedside, clinicians can determine the most effective antibiotic treatment without the typical multi-day delay associated with standard urine cultures.
This development addresses a critical challenge in clinical practice: the rising prevalence of antibiotic-resistant infections. By ensuring patients receive targeted treatment immediately, the system aims to reduce the reliance on broad-spectrum antibiotics and improve patient outcomes.